CMND Archives - BioTuesdays

Developments

Clearmind doses first patient in trial of MEAI-based treatment for AUD

Clearmind Medicine (NASDAQ: CMND; FSE: CWY0) has announced that the first patient has been dosed in its Phase 1/2a clinical trial of its proprietary MEAI-based oral drug candidate, CMND-100, for the treatment of alcohol...

July 2, 2025

Developments

Clearmind adds leading Israeli clinical site to ongoing trial of CMND-100 in AUD

Clearmind Medicine (NASDAQ: CMND; FSE: CWY0) has announced that it has added Tel Aviv Sourasky Medical Center (TASMC) to the list of clinical sites for its ongoing Phase 1/2a trial evaluating CMND-100—a proprietary MEAI...

June 24, 2025

Developments

Clearmind initiates first U.S. trial of CMND-100 in AUD at Johns Hopkins

Clearmind Medicine (NASDAQ:CMND; FSE:CWYO) announced the initiation of its first U.S.-based Phase 1/2a trial of CMND-100 in alcohol use disorder (AUD) at the Johns Hopkins University School of Medicine. According to...

April 11, 2025

Developments

Clearmind granted patent for binge behavior treatment in Macau

Clearmind Medicine (NASDAQ:CMND; FSE:CWY0) has announced that its proprietary MEAI-based binge behavior regulator program has received patent approval from the Macau International Intellectual Property Office, a special...

January 3, 2025

Feature

Clearmind spearheading novel, life-changing psychedelic solutions for binge behaviors and mental health

Clearmind Medicine (NASDAQ:CMND; FSE:CWY0) is discovering and developing safe, novel psychedelic-derived therapeutic candidates with its new psychoactive molecule, 5-Methoxy-2-aminoindane (MEAI), to address widespread...

November 26, 2024

Developments

Clearmind receives IRB approval for trial of CMND-100 for AUD at second clinical site

Clearmind Medicine (NASDAQ:CMND) has announced that it has received Institutional Review Board (IRB) approval from one of its U.S. clinical sites for part A of its Phase I/IIa clinical trial of CMND-100 for the...

October 10, 2024

Developments

Clearmind files additional U.S. patent application for MEAI to treat obesity

Clearmind Medicine (NASDAQ:CMND; FSE:CWYO) announced it has filed an additional patent application with the USPTO for the novel proprietary composition of its MEAI compound for treating metabolic syndrome and obesity...

July 16, 2024

Tag - CMND

Clearmind doses first patient in trial of MEAI-based treatment for AUD

Clearmind adds leading Israeli clinical site to ongoing trial of CMND-100 in AUD

Clearmind initiates first U.S. trial of CMND-100 in AUD at Johns Hopkins

Clearmind granted patent for binge behavior treatment in Macau

Clearmind spearheading novel, life-changing psychedelic solutions for binge behaviors and mental health

Clearmind receives IRB approval for trial of CMND-100 for AUD at second clinical site

Clearmind files additional U.S. patent application for MEAI to treat obesity

Subscribe